Cargando…

Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes

BACKGROUND AND AIMS: Inflammatory bowel disease [IBD] phenotypes are very heterogeneous between patients, and current clinical and molecular classifications do not accurately predict the course that IBD will take over time. Genetic determinants of disease phenotypes remain largely unknown but could...

Descripción completa

Detalles Bibliográficos
Autores principales:	Voskuil, M D, Spekhorst, L M, van der Sloot, K W J, Jansen, B H, Dijkstra, G, van der Woude, C J, Hoentjen, F, Pierik, M J, van der Meulen, A E, de Boer, N K H, Löwenberg, M, Oldenburg, B, Festen, E A M, Weersma, R K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218708/ https://www.ncbi.nlm.nih.gov/pubmed/33152062 http://dx.doi.org/10.1093/ecco-jcc/jjaa223

Ejemplares similares

Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
por: Biemans, Vince B C, et al.
Publicado: (2020)

The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease
por: Spekhorst, Lieke M, et al.
Publicado: (2017)

Correction to: The 1000IBD project: multi-omics data of 1000 inflammatory bowel disease patients; data release 1
por: Imhann, Floris, et al.
Publicado: (2019)

Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis
por: Simsek, Melek, et al.
Publicado: (2019)

Vedolizumab for Inflammatory Bowel Disease: Two‐Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry – Vedolizumab
por: Biemans, Vince B.C., et al.
Publicado: (2019)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease
por: Karmi, Naomi, et al.
Publicado: (2021)

Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2
por: Visschedijk, Marijn C., et al.
Publicado: (2016)

Environmental factors associated with biological use and surgery in inflammatory bowel disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study
por: Goetgebuer, R L, et al.
Publicado: (2021)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Large-scale genetic analyses in an understudied disease: haemorrhoidal disease
por: Festen, Eleonora A M, et al.
Publicado: (2021)

Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease
por: Hu, Shixian, et al.
Publicado: (2021)

Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
por: Nijmeijer, Rian M., et al.
Publicado: (2011)

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

The opposite end of the attention deficit hyperactivity disorder continuum: genetic and environmental aetiologies of extremely low ADHD traits
por: Greven, Corina U., et al.
Publicado: (2015)

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease
por: Otten, Antonius T., et al.
Publicado: (2022)

Development and validation of a web-based questionnaire to identify environmental risk factors for inflammatory bowel disease: the Groningen IBD Environmental Questionnaire (GIEQ)
por: van der Sloot, Kimberley Wilhelmina Johanna, et al.
Publicado: (2018)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
por: Loveikyte, Roberta, et al.
Publicado: (2023)

Impact of timing of primary ileocecal resection on prognosis in patients with Crohn’s disease
por: Beelen, Evelien M J, et al.
Publicado: (2023)

Donor genetic variants as risk factors for thrombosis after liver transplantation: A genome‐wide association study
por: Li, Yanni, et al.
Publicado: (2021)

Genetic and environmental aetiology of the dimensions of Callous-Unemotional traits
por: Henry, J., et al.
Publicado: (2016)

Genetic and environmental influences on MRI scan quantity and quality
por: Achterberg, Michelle, et al.
Publicado: (2019)

Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
por: Bourgonje, Arno R., et al.
Publicado: (2021)

Genetic and environmental influences on structure of the social brain in childhood
por: van der Meulen, Mara, et al.
Publicado: (2020)

Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
por: Nuij, V. J. A. A., et al.
Publicado: (2017)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Genetic and Non-Genetic Inheritance of Natural Antibodies Binding Keyhole Limpet Hemocyanin in a Purebred Layer Chicken Line
por: Berghof, T. V. L., et al.
Publicado: (2015)

Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life
por: Kanis, Shannon Linda, et al.
Publicado: (2021)

Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
por: Voskuil, Michiel Dirk, et al.
Publicado: (2019)

Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease
por: Bangma, Amber, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
por: Jansen, Fenna M, et al.
Publicado: (2023)

Genetic Association Analysis of the Functional c.714T>G Polymorphism and Mucosal Expression of Dectin-1 in Inflammatory Bowel Disease
por: de Vries, Hilbert S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_42f7t36pj5q76d976qrr54nbv6